Pfizer said yesterday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study.
Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduce the bleeding rate in patients with moderately severe to severe forms of hemophilia B.
The disorder hampers the body’s ability to make a blood-clotting protein called factor IX.
Pfizer’s therapy, fidanacogene elaparvovec, is designed to help patients produce factor IX themselves after a one-time treatment, as opposed to current treatments, which focus on regular infusions of the protein.
The drugmaker licensed its hemophilia B gene therapy from Roche’s Spark Therapeutics unit in 2014 for a $20-million upfront payment.
Pfizer plans to discuss the late-stage data with regulatory authorities in Europe and the United States (US) and share additional data for the experimental therapy at a scientific conference in early 2023.
In November, the US health regulator approved the first gene therapy, CSL and uniQure’s Hemgenix, to treat hemophilia B.
Pfizer is also testing other experimental gene therapies in late-stage trials as potential treatments for the bleeding disorder hemophilia A and muscular disorder Duchenne muscular dystrophy.
Edits by EP News Bureau
thanks for sharing such a nice information